Esorate-L Capsule SR is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and dyspepsia. Esomeprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing symptomatic relief and promoting healing in acid-related conditions. The sustained-release formulation of Esorate-L ensures prolonged therapeutic plasma concentrations, enhancing efficacy and patient compliance. This combination is indicated for the treatment of gastroesophageal reflux disease (GERD), functional dyspepsia, gastritis, and other acid-peptic disorders where both acid suppression and improved gastric motility are desired. Esorate-L Capsule SR should be administered under medical supervision, considering contraindications such as hypersensitivity to either component and caution in patients with renal or hepatic impairment. Common adverse effects may include headache, dizziness, and gastrointestinal disturbances. This dual-action therapy offers a comprehensive approach to managing complex gastrointestinal symptoms by addressing both motility dysfunction and acid hypersecretion.